DFDA

Intravenous Immunoglobulin (IVIG)

Treatment for Myocarditis

Typical Dosage: 1-2 g/kg total dose

Effectiveness
60%
Safety Score
60%
Clinical Trials
2
Participants
1K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
1-2 g/kg total dose
Time to Effect
Days to weeks
Treatment Duration
2-5 day course
Evidence Quality
LOW
Confidence Score
55%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$25,000
Monitoring:$750
Side Effect Mgmt:$100
Total Annual:$25,850
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
QALYs Gained
0.7
Outcome-Based Costs
Cost per Responder
$51,700
Cost per Remission
$86,167
Intravenous Immunoglobulin (IVIG) Outcomes

for Myocarditis

Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+50%
Remission Rate
+30%
Common Side Effects
Headache
+25%
Fever/Chills
+15%
Infusion reactions
+8%
Renal dysfunction
+1%

Sources:

nih.gov
jst.go.jp
researchgate.net

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
1 active trial recruiting for Intravenous Immunoglobulin (IVIG) in Myocarditis

Pulse Corticosteroids Or/and Immunoglobulins to Treat Fulminant Myocarditis

NCT06896253NOT YET RECRUITINGPHASE2
View Study
120 participants
INTERVENTIONAL
Started: Apr 1, 2025